Cryolife Inc (NYSE:CRY) VP John E. Davis sold 3,333 shares of the stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $33.86, for a total value of $112,855.38. Following the sale, the vice president now directly owns 52,564 shares in the company, valued at approximately $1,779,817.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
John E. Davis also recently made the following trade(s):
- On Thursday, July 26th, John E. Davis sold 3,391 shares of Cryolife stock. The shares were sold at an average price of $31.00, for a total value of $105,121.00.
NYSE:CRY traded up $0.55 during trading hours on Friday, hitting $30.13. 146,368 shares of the company were exchanged, compared to its average volume of 131,751. The firm has a market cap of $1.29 billion, a P/E ratio of 75.33 and a beta of 0.61. The company has a quick ratio of 3.63, a current ratio of 4.97 and a debt-to-equity ratio of 0.80. Cryolife Inc has a one year low of $16.80 and a one year high of $36.05.
Cryolife (NYSE:CRY) last announced its earnings results on Monday, August 6th. The medical equipment provider reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. Cryolife had a positive return on equity of 4.28% and a negative net margin of 2.34%. The business had revenue of $68.50 million during the quarter, compared to analyst estimates of $64.08 million. During the same period last year, the company earned $0.12 EPS. Cryolife’s revenue for the quarter was up 43.2% compared to the same quarter last year. As a group, equities research analysts expect that Cryolife Inc will post 0.31 EPS for the current year.
A number of research analysts have recently commented on CRY shares. Zacks Investment Research cut Cryolife from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Northland Securities reiterated a “buy” rating and issued a $32.00 price target on shares of Cryolife in a research note on Tuesday, August 7th. Finally, Canaccord Genuity raised their target price on Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. One research analyst has rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $35.00.
Several hedge funds have recently bought and sold shares of CRY. United Services Automobile Association acquired a new stake in shares of Cryolife in the 2nd quarter valued at about $208,000. Northern Trust Corp grew its stake in shares of Cryolife by 3.3% in the 2nd quarter. Northern Trust Corp now owns 1,209,826 shares of the medical equipment provider’s stock valued at $33,694,000 after buying an additional 38,921 shares during the period. Bank of America Corp DE grew its stake in shares of Cryolife by 3.7% in the 2nd quarter. Bank of America Corp DE now owns 127,412 shares of the medical equipment provider’s stock valued at $3,548,000 after buying an additional 4,517 shares during the period. Citadel Advisors LLC grew its stake in shares of Cryolife by 33.1% in the 2nd quarter. Citadel Advisors LLC now owns 37,366 shares of the medical equipment provider’s stock valued at $1,041,000 after buying an additional 9,296 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Cryolife by 8.2% in the 2nd quarter. Legal & General Group Plc now owns 66,700 shares of the medical equipment provider’s stock valued at $1,853,000 after buying an additional 5,051 shares during the period. 68.92% of the stock is owned by hedge funds and other institutional investors.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Featured Article: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.